FDA Drug Safety Changes Will Not Affect Oncology Therapies, Agency's Pazdur Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's safety overhaul "will not tamper with" drugs for life-threatening conditions, Office of Oncology Drug Products Director Pazdur tells the American Society of Clinical Oncology annual meeting. FDAer suggests the cancer community could provide insight into improved safety surveillance.